Our Proprietary Pipeline - A Journey of Hope, Innovation, and Transformation
Pharmaeconomica is advancing its drug discovery pipeline to address high unmet needs. We are developing brain-specific, highly selective BChE inhibitors for neurological conditions. Our multi-target research aims at compounds targeting MDM2, gamma-secretase, BACE1, and TAU for neurodegenerative diseases. In the antiviral domain, we have promising compounds against Ebola glycoproteins and are researching multitargeted compounds for HIV proteins. Additionally, we are identifying GPR10 receptor agonists for treating metabolic disorders. Our focused approach promises innovative treatments with significant therapeutic potential, offering attractive investment opportunities.​
Exploring new frontiers, finding hidden gems within a vast array of compounds.
Pharmaeconomica is at the forefront of accelerating drug discovery through advanced AI and machine learning methodologies that enable effective hit identification, significantly saving time and resources. Our comprehensive in-house database, rich in diverse lead compounds and peptides, combined with a robust suite of predictive modeling tools for ADMET, physicochemical property prediction, target prediction, and lead optimization, ensures the highest quality candidates for development. We invite potential collaborators to leverage our cutting-edge platform to expedite the discovery and development of innovative therapies, driving forward transformative advancements in healthcare.
​
Computational drug discovery is transforming the industry. Techniques like Molecular Dynamics (MD) simulations and Quantitative Structure-Property Relationship (QSPR) modeling solve complex biological problems, leading to more effective drugs and higher clinical trial success rates.
